More jumping on the Cleveland Biolabs bandwagon Print E-mail
By M.E.Garza   
Wednesday, 02 February 2011 09:42

Another analyst thinks Cleveland Biolabs (Nasdaq:CBLI) is headed higher. The stock has been initiated with an Outperform rating and a target price of $10 by Wedbush.

Close-Up: Cleveland BioLabs' Anti-Cancer Effect Excites Investors

Presentation sheds light on significant upcoming developments for Cleveland Biolabs

Wedbush Securities is one of the largest securities firms and investment banks in the nation. The firm notes the company is developing CBLB502, an injectable protein, as a treatment for Acute Radiation Syndrome and as a radio-protectant in radiation oncology.

It further notes that human studies have shown CBLB502 to be safe in a Phase I/II study; animal studies have demonstrated protection against ARS.

The estimates for the total market for CBLB502 is $300 million in annual revenues, taking into account military, civilian and likely foreign demand. Wedbush expects that the company will be awarded a contract to supply the US government with CBLB502 to prevent ARS in the event of a radiological event.

BioMedReports has been telling our readers about CBLI since the stock was under $3, and we continue to believe that the firm will receive another  large government grant in somewhere between $50 and $100 million dollars in the very near future. We noted that fact after a recent presentation by the company and feel that this grant will lead to orders for the drug from not only the U.S. government, but also some of its allies- namely Israel.

We also continue to beleive that CBLB502 is poised become one of the most interesting cancer immunotherapy drug candidates in the space, given the recent news announcement made by the company. In fact, as I pointed out in a recent article, 502 as a cancer treatment may be further along than most of the market anticipates given the human safety and manufacturing data that is already in the hands of the FDA given the drugs fast tracked development as a treatment for ARS.

In addition, as I said in my earlier report, what Cleveland is proposing here is an off-the-shelf drug that does not have to be tailored to the specific patient. It does not involve the timely and expensive re-programming of the body’s dendritic cells and perhaps because of those factors, the potential cost of treatment would not be as prohibitive as some of the existing immunotherapy drugs which are on the way to market now.

We urge our readers to research the company and to read our previous articles and coverage on the company as we believe shares will appreciate in price substantially from these levels.

On Tuesday morning, we issued a trade alert to our subscribers after Ray Dirks published his report on the company and re-iterated his own BUY recommendation. Shares rose and are currently trading just under their 50-day moving average and significantly higher than their 200-day moving average.

Disclosure: Long CBLI

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus